Merck & Co., headquartered in Rahway, New Jersey, employs 72,000 people and provides health solutions through pharmaceuticals, vaccines, and animal health products. Its lead candidate is MK-6070, targeting DLL3.
MRK filed a patent for "rna interference mediated inhibition of prolyl hydroxylase domain 2 (phd2) gene expression using short interfering nucleic acid (sina)" on Mon, March 4, 2024. The patent was officially published on Thu, February 27, 2025.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
